Cargando…

Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting

BACKGROUND: Lung cancer (LC) chemotherapy results in several adverse events (AEs). Data regarding supportive care medications (SCMs) offered to prevent/treat AEs in resource-limited settings are lacking. A prospective observational study was carried out to find the effectiveness of SCMs in real-life...

Descripción completa

Detalles Bibliográficos
Autores principales: Muthu, Valliappan, Mylliemngap, Badari, Prasad, Kuruswamy Thurai, Behera, Digambar, Singh, Navneet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330793/
https://www.ncbi.nlm.nih.gov/pubmed/30604703
http://dx.doi.org/10.4103/lungindia.lungindia_321_17
_version_ 1783387035443134464
author Muthu, Valliappan
Mylliemngap, Badari
Prasad, Kuruswamy Thurai
Behera, Digambar
Singh, Navneet
author_facet Muthu, Valliappan
Mylliemngap, Badari
Prasad, Kuruswamy Thurai
Behera, Digambar
Singh, Navneet
author_sort Muthu, Valliappan
collection PubMed
description BACKGROUND: Lung cancer (LC) chemotherapy results in several adverse events (AEs). Data regarding supportive care medications (SCMs) offered to prevent/treat AEs in resource-limited settings are lacking. A prospective observational study was carried out to find the effectiveness of SCMs in real-life setting. METHODS: Newly diagnosed LC patients receiving first-line chemotherapy at a tertiary referral center in North India (from July 2014 to September 2015) were enrolled. Incidence, timing of onset, duration, and grades of chemotherapy-related AEs were recorded. We assessed compliance to mandatory SCMs using a structured questionnaire. Patients also recorded various symptoms, frequency of need-based SCMs, visits to local practitioners, and hospitalization (if any) during the intercycle period. RESULTS: Of the 112 patients enrolled, majority were males (83.9%, n = 94), current/ex-smokers (82.1%, n = 92), had advanced stage (Stage IIIB = 33.9% [n = 38] and Stage IV = 46.4% [n = 52]), and were non-small cell lung cancer (72.3%, n = 81). AEs were reported in 566 cycles (94%) out of a total of 602 chemotherapy cycles. Diarrhea was the most common AE (180 cycles, 29.9%) developing after a mean (standard deviation) duration of 3.6 (2.5) days and lasting for 4 (3.3) days. Vomiting (138 cycles, 22.9%) and constipation (121 cycles, 20.1%) were other common AEs. Grade 3/4 AEs occurred in 6.9% (39/566) cycles. Need-based SCMs were required in 479 of the 566 cycles (84.6%). Proportion of patients with Grade 3/4 AEs and hospitalization was highest for mucositis (16.1% Grade 3/4 and 9.7% hospitalized); followed by vomiting (10.1% Grade 3/4 and 8.7% hospitalized). Anemia was seen in 441 of 602 chemotherapy cycles (73.3%). Frequency and severity of anemia continued to increase with each chemotherapy cycle. CONCLUSION: LC chemotherapy has a high prevalence of AEs. However, the majority are low grade recovering with need-based SCMs, without any need for hospitalization.
format Online
Article
Text
id pubmed-6330793
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-63307932019-04-17 Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting Muthu, Valliappan Mylliemngap, Badari Prasad, Kuruswamy Thurai Behera, Digambar Singh, Navneet Lung India Original Article BACKGROUND: Lung cancer (LC) chemotherapy results in several adverse events (AEs). Data regarding supportive care medications (SCMs) offered to prevent/treat AEs in resource-limited settings are lacking. A prospective observational study was carried out to find the effectiveness of SCMs in real-life setting. METHODS: Newly diagnosed LC patients receiving first-line chemotherapy at a tertiary referral center in North India (from July 2014 to September 2015) were enrolled. Incidence, timing of onset, duration, and grades of chemotherapy-related AEs were recorded. We assessed compliance to mandatory SCMs using a structured questionnaire. Patients also recorded various symptoms, frequency of need-based SCMs, visits to local practitioners, and hospitalization (if any) during the intercycle period. RESULTS: Of the 112 patients enrolled, majority were males (83.9%, n = 94), current/ex-smokers (82.1%, n = 92), had advanced stage (Stage IIIB = 33.9% [n = 38] and Stage IV = 46.4% [n = 52]), and were non-small cell lung cancer (72.3%, n = 81). AEs were reported in 566 cycles (94%) out of a total of 602 chemotherapy cycles. Diarrhea was the most common AE (180 cycles, 29.9%) developing after a mean (standard deviation) duration of 3.6 (2.5) days and lasting for 4 (3.3) days. Vomiting (138 cycles, 22.9%) and constipation (121 cycles, 20.1%) were other common AEs. Grade 3/4 AEs occurred in 6.9% (39/566) cycles. Need-based SCMs were required in 479 of the 566 cycles (84.6%). Proportion of patients with Grade 3/4 AEs and hospitalization was highest for mucositis (16.1% Grade 3/4 and 9.7% hospitalized); followed by vomiting (10.1% Grade 3/4 and 8.7% hospitalized). Anemia was seen in 441 of 602 chemotherapy cycles (73.3%). Frequency and severity of anemia continued to increase with each chemotherapy cycle. CONCLUSION: LC chemotherapy has a high prevalence of AEs. However, the majority are low grade recovering with need-based SCMs, without any need for hospitalization. Medknow Publications & Media Pvt Ltd 2019 /pmc/articles/PMC6330793/ /pubmed/30604703 http://dx.doi.org/10.4103/lungindia.lungindia_321_17 Text en Copyright: © 2018 Indian Chest Society http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Muthu, Valliappan
Mylliemngap, Badari
Prasad, Kuruswamy Thurai
Behera, Digambar
Singh, Navneet
Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting
title Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting
title_full Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting
title_fullStr Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting
title_full_unstemmed Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting
title_short Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting
title_sort adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330793/
https://www.ncbi.nlm.nih.gov/pubmed/30604703
http://dx.doi.org/10.4103/lungindia.lungindia_321_17
work_keys_str_mv AT muthuvalliappan adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting
AT mylliemngapbadari adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting
AT prasadkuruswamythurai adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting
AT beheradigambar adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting
AT singhnavneet adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting